Key Takeaways
- • FDA submitted its FY2027 budget proposal to Congress totaling $7.2B ($3.3B appropriations + $3.9B user fees), representing a 3.3% increase ($232M) over FY2026 spending levels.
- • FDA rejected a petition for partial 510(k) exemption covering radiology software products including Computer-Aided Detection (CAD), Computer-Aided Diagnosis (CADx), and Computer-Aided Triage and Notification (CADt) devices, determining exemptions would not serve the public interest and lack legal authority.
- • Former FDA Center for Devices and Radiological Health (CDRH) leadership launched White Oak 66 Capital, a new venture capital fund co-founded by ex-CDRH Director Jeff Shuren, former Chief Scientist and Deputy Director Douglas Kelly, and Ross Segan (former director of the Office of Product Evaluation and Quality).
Summary
The FDA advanced three significant regulatory and organizational developments this week that warrant attention from institutional investors and medtech stakeholders. The agency's formal budget submission to Congress outlined total spending of $7.2 billion for fiscal year 2027, comprising $3.3 billion in direct appropriations and $3.9 billion in user fees. The proposed budget represents a modest 3.3% increase ($232 million) relative to FY2026 levels, reflecting the agency's ongoing operational and regulatory priorities.
In a substantial regulatory decision, the FDA issued a final response letter rejecting a petition for partial exemption from 510(k) premarket notification requirements for certain radiological software products. The rejected petition encompassed multiple device categories including Computer-Aided Detection (CAD), Computer-Aided Diagnosis (CADx), and Computer-Aided Triage and Notification (CADt) systems, as well as medical image analyzers and radiological computer-assisted diagnostic software. The FDA's determination reflects the agency's position that granting such exemptions would not serve public health interests and that the agency lacks legal authority to implement the requested changes under existing regulatory frameworks.
The week's third notable development involves high-level personnel movement within the medtech ecosystem. Several prominent former FDA officials from the Center for Devices and Radiological Health have launched White Oak 66 Capital, a new venture capital fund positioned to invest in medical device and regulatory technology sectors. The co-founders include Jeff Shuren, who previously directed CDRH; Douglas Kelly, former CDRH Chief Scientist and Deputy Director; and Ross Segan, who led the Office of Product Evaluation and Quality. This development signals potential institutional capital influx into medtech ventures backed by regulatory expertise and FDA-insider perspectives on compliance and approval pathways.
In a substantial regulatory decision, the FDA issued a final response letter rejecting a petition for partial exemption from 510(k) premarket notification requirements for certain radiological software products. The rejected petition encompassed multiple device categories including Computer-Aided Detection (CAD), Computer-Aided Diagnosis (CADx), and Computer-Aided Triage and Notification (CADt) systems, as well as medical image analyzers and radiological computer-assisted diagnostic software. The FDA's determination reflects the agency's position that granting such exemptions would not serve public health interests and that the agency lacks legal authority to implement the requested changes under existing regulatory frameworks.
The week's third notable development involves high-level personnel movement within the medtech ecosystem. Several prominent former FDA officials from the Center for Devices and Radiological Health have launched White Oak 66 Capital, a new venture capital fund positioned to invest in medical device and regulatory technology sectors. The co-founders include Jeff Shuren, who previously directed CDRH; Douglas Kelly, former CDRH Chief Scientist and Deputy Director; and Ross Segan, who led the Office of Product Evaluation and Quality. This development signals potential institutional capital influx into medtech ventures backed by regulatory expertise and FDA-insider perspectives on compliance and approval pathways.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.